- For the second time running, GENEART is one of the 50 most dynamic Bavarian companies. - Since 2000, annual sales have grown on average by above 70%. - Furthermore GENEART is one of the few profitable life science companies in Germany. - GENEART expects to keep up its unbroken growth dynamics in 2007. Regensburg / Munich, June 19, 2007. GENEART AG is the recipient of the "BAYERNS BEST 50 / BAVARIA'S BEST 50" award for the second time running. The Bavarian Ministry of State honors GENEART for being one of the 50 fastest-growing companies in Bavaria. As one of the few profitable biotechnology companies in Germany, the Regensburg based specialist for synthetic genes and for synthetic biology was able to convince the jury of Ernst & Young with an average annual sales growth rate above 70% since the year 2000 and the growing staff of now more than 120 employees. Last night, Bavaria's Minister of Economic Affairs Erwin Huber honored the 50 most dynamic Bavarian enterprises. The award was established six years ago and goes to companies, which have demonstrated strong growth with increases in sales and personnel in recent years. With its extraordinary sustained growth dynamics in recent years GENEART is one of Bavaria's model enterprises. The company has entered the synthetic gene market in 2000 and has since become the global market leader in this field. On average, the annual sales have increased in this time by more than 70%. In 2006, sales have grown by 72 % to EUR 7.8M. The operating result (EBIT) for this period were EUR 1.0M. GENEART was able to continue the growth trend in the first quarter 2007 with an increase in total revenues to EUR 3.1M. This is a 68% increase over the same period in the prior year. In the first quarter, the operating result (EBIT) increased to EUR 0.4M and the earnings before taxes grew to EUR 0.5M. The IPO in 2006 provided GENEART with sufficient funds to sustain the profitable growth and to strengthen its leadership position in the global markets. "Our technology leadership in the gene synthesis field and the largest production capacities will enable us to continue taking full advantage of the dynamic development in the global synthetic biology market. Meanwhile, our first rate technology "made in Bavaria" has become an indispensable tool in the development of innovative therapeutics and vaccines for the pharmaceutical industry. The technology also helps to improve industrial enzymes in the industrial biotechnology. The highly qualified work force in the Regensburg region provide a good setting to further improve our competitive position in the market", comments Professor Dr. Ralf Wagner, CEO of the GENEART AG at the festive award ceremony. Photographs of the prize winner award ceremony will be available beginning Tuesday, June 19, 2007. For further inquiries please contact: Bernd Merkl Frank Ostermair GENEART AG Haubrok Investor Relations GmbH Josef-Engert-Str. 11 Maximilianstr. 45 D-93053 Regensburg 80538 Munich Tel.: +49-(0)941-942 76 - 38 Tel: +49-(0)89-461347-10 Fax: +49-(0)941-942 76 - 75 Fax: +49-(0)89-461347-29 [email protected] [email protected] www.geneart.com Legal Information This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results. Background Information About GENEART AG In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the synthetic biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto (Canada) employ more than 120 people. Since May 2006, GENEART is listed on the German Stock Exchange. BAYERNS BEST 50 The BAYERNS BEST 50 award will be granted for the sixth time on June 18, 2007. Tonight, the Bavarian Minister Erwin Huber honors, the 50 most dynamic companies that have shown unusually strong growth for the last few years and saw higher-than-average increases in both sales and job creation with a ceremony in the Kaisersaal of the residence in Munich. The award ceremony should send the right signals and at the same time also encourage both start-up entrepreneurs and medium-sized businesses in Bavaria. Evaluation for BAYERNS BEST 50 was performed by the audit firm Ernst & Young AG in 2007, and ranking was according to the Birch Index, with the main criteria being growth in both revenue and job creation. For information, go to www.bb50.de.